UK markets closed

Allarity Therapeutics A/S (ALLR.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
0.8745-0.0055 (-0.63%)
At close: 5:29PM CEST
Full screen
Previous close0.8800
Open0.8985
Bid0.8660 x N/A
Ask0.8715 x N/A
Day's range0.8520 - 0.8985
52-week range0.6134 - 2.1600
Volume1,254,576
Avg. volume2,671,399
Market cap211.438M
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)-0.2680
Earnings date28 Aug 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib

    Oncoheroes will fund and advance clinical development of both dovitinib and stenoparib in pediatric cancersAllarity is preparing to file a first U.S. new drug application (NDA) for the approval of dovitinib in renal cell carcinoma (RCC), and has been planning for an additional clinical trial of the drug in a pediatric cancer, utilizing its DRP® companion diagnostic for dovitinibAllarity is also currently conducting a Phase 2 study of stenoparib in ovarian cancer utilizing its DRP® companion diag

  • Globe Newswire

    Allarity Therapeutics Completes Oversubscribed Rights Issue

    – Allarity raises SEK 102.8 million before issue costs to further finance the development of three high-priority pipeline programs – The Rights Issue of Units was subscribed for approximately 106 percent, without the use of guarantors’ commitments Press release Hørsholm, Denmark (10 June 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced the outcome of the Rights Issue of Units, consisting of shares and warrants series TO 3, resolved upon by the Board of Directors on 1

  • Globe Newswire

    Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic

    – Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib – Poster provides new details of the DRP® companion diagnostic for dovitinib, its lead oncology pipeline asset Press release Hørsholm, Denmark (9 June 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of an e-Poster titled ‘A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib’ at the